Page last updated: 2024-11-07

neurotensin (8-13)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

neurotensin (8-13): binds in human brain to the same site as neurotensin but with higher affinity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123783
MeSH IDM0153606

Synonyms (8)

Synonym
arg-arg-pro-tyr-ile-leu
60482-95-3
2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
l-leucine, n-(n-(n-(1-(n2-l-arginyl-l-arginyl)-l-prolyl)-l-tyrosyl)-l-isoleucyl)-
arginyl-arginyl-prolyl-tyrosyl-isoleucyl-leucine
neurotensin (8-13)
n-(2-{[2-{[{1-[n~2~-(2-amino-5-carbamimidamido-1-hydroxypentylidene)arginyl]pyrrolidin-2-yl}(hydroxy)methylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-3-methylpentylidene)leucine
DTXSID50975895

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Here, we thus hypothesized that the combined use of opioid and NT agonists would require lower doses to produce significant analgesic effects, hence decreasing opioid-induced adverse effects."( The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio.
Blais, V; Côté, J; Eiselt, E; Gendron, L; Longpré, JM; Sarret, P, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" However, limited peptide stability and oral bioavailability have prevented these compounds from being developed as relevant pharmaceuticals."( Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
Dix, TA; Hadden, MK; Kokko, KP; Mazella, J; Orwig, KS, 2005
)
0.55

Dosage Studied

ExcerptRelevanceReference
" Chronic dosing (5mg/kg) of this compound over 5 consecutive days failed to induce hypothermic tolerance while the same dose failed to induce measurable catalepsy."( In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier.
Dix, TA; Hadden, MK; Kokko, KP; Orwig, KS; Price, KL; See, RE, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.62)18.7374
1990's21 (32.31)18.2507
2000's29 (44.62)29.6817
2010's12 (18.46)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.29 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (98.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]